NuView Life Sciences is a biotechnology company based in Park City, Utah that is focused on precision cancer diagnostics and therapeutics improving patient outcomes and reducing healthcare costs. Founded in 2005, their mission is to change the way many types of cancer are diagnosed and treated using precision medicine technology. The company believes that diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers. NuView aims to accomplish this through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1(TM). Their leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer. Attaching a molecular imaging or therapeutic component to a NV-VPAC1(tm) peptide enables NuView Life Sciences to develop a series of precisely targeted products that may be used in the diagnosis and treatment of cancer. The NV-VPAC1TM technology is also being developed as an in vitro diagnostic kit by attaching a fluorophore to an NV-VPAC1TM peptide that may be used for detecting shed cancer cells in voided urine. The company intends to develop therapeutic applications of the NV-VPAC1(tm) technology by bringing forward peptide analogs that link cytotoxic agents (chemotherapy) or beta-emitting isotopes (cancer killing isotopes). One example of an isotope that may be used for the treatment of cancer is Copper-67. Targeted therapeutics have the potential to improve efficacy and reduce patient toxicity. For more information on NuView Life Sciences, please visit their website.